Abstract | BACKGROUND: METHODS: Before the research, we conducted a comprehensive search on relevant websites. Two professional researchers will gradually screen, read the title, abstract and full text if necessary, and independently select qualified documents according to the inclusion and exclusion criteria. We will conduct a meta-analysis of the results related to COVID-19 to assess the risks of bias and data extraction. The heterogeneity of data will be studied by Cochrane X and I tests. The evaluation of publication bias will be carried out by funnel chart analysis and Eger test. RESULTS: This review will be disseminated in print by peer-review. CONCLUSION: Our research is to scientifically analyze the clinical evidence of Xuebijing injection in treating severe COVID-19 patients.
|
Authors | Jiaming Fu, Lili Wu, Yingying Ma, Qun Liang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 99
Issue 49
Pg. e23401
(Dec 04 2020)
ISSN: 1536-5964 [Electronic] United States |
PMID | 33285727
(Publication Type: Journal Article)
|
Chemical References |
- Drugs, Chinese Herbal
- Xuebijing
|
Topics |
- COVID-19
(physiopathology)
- Clinical Trials as Topic
- Drugs, Chinese Herbal
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Infusions, Intravenous
- Medicine, Chinese Traditional
- Pandemics
- Research Design
- SARS-CoV-2
- Severity of Illness Index
- COVID-19 Drug Treatment
- Meta-Analysis as Topic
- Systematic Review as Topic
|